LATEST NEWS

A phase I dose expansion study of NBTXR3, radiation enhancing hafnium oxide nanoparticles, for the treatment of cisplatin-ineligible locally advanced HNSCC patients

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.